Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
86.5M
-
Shares change
-
-831K
-
Total reported value, excl. options
-
$3.05B
-
Value change
-
-$11.4M
-
Put/Call ratio
-
0.29
-
Number of buys
-
72
-
Number of sells
-
-87
-
Price
-
$35.30
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2021
204 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q1 2021.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.5M shares
of 226M outstanding shares and own 38.25% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (18.7M shares), Capital Research Global Investors (12.7M shares), Capital International Investors (6.6M shares), BlackRock Inc. (6.27M shares), VANGUARD GROUP INC (5.96M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.46M shares), ALLIANCEBERNSTEIN L.P. (2.54M shares), JPMORGAN CHASE & CO (2.38M shares), STATE STREET CORP (2.33M shares), and Capital World Investors (2.25M shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.